¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Prothrombin mutation G20210A"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® mutation ÇÑ±Û µ¹¿¬º¯ÀÌ
¼³¸í   
  ¼¼Æ÷ÀÇ dna ÀÚüÀÇ º¯ÀÌ¿¡ ÀÇÇØ ÀϾ´Â ¼¼Æ÷º¯À̸¦ ¸»ÇÑ´Ù. ÀÌ·¯ÇÑ °æ¿ì µ¹¿¬º¯À̷ΠÀϾ ¼¼Æ÷´Â ±× ÀÌÈÄ µþ¼¼Æ÷(daughter cell)¿¡¼­µµ ±× º¯À̰¡ ¿©ÀüÈ÷ À¯ÁöµÇ¹Ç·Î Á¾(species)ÀÇ º¯È­³ª, È¤Àº ¼¼Æ÷ÀÇ ¾Ç¼ºº¯È¯(malignant transformation)¿¡ °ü¿©ÇÑ´Ù.
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • allelic mutation
    ¸Â¼¶µ¹¿¬º¯ÀÌ, ´ë¸³µ¹¿¬º¯ÀÌ
  • back mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • cold-sensitive mutation
    Àú¿Â¹Î°¨µ¹¿¬º¯ÀÌ, Àú¿Â°¨¼ö¼ºµ¹¿¬º¯ÀÌ
  • conditional lethal mutation
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°Çµ¹¿¬º¯ÀÌ
  • chromosomal mutation
    ¿°»öüµ¹¿¬º¯ÀÌ
  • chromosome mutation
    ¿°»öüµ¹¿¬º¯ÀÌ
  • drift mutation
    ¿¬¼Óº¯ÀÌ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • extragenic suppressor mutation
    À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
  • forward mutation
    ¾ÕÂʵ¹¿¬º¯ÀÌ, ÀüÇâµ¹¿¬º¯ÀÌ
  • frameshift mutation
    ƲÀ̵¿µ¹¿¬º¯ÀÌ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • mutation
    µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • back mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • chromosomal mutation
    ¿°»öüº¯ÀÌ, ¿°»öüµ¹¿¬º¯ÀÌ
  • cold-sensitive mutation
    Àú¿Â¹Î°¨µ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°Çµ¹¿¬º¯ÀÌ
  • conditional lethal mutation
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • drift mutation
    ¿¬¼Óº¯ÀÌ
  • mutation detection
    µ¹¿¬º¯À̰ËÃâ
  • extragenic suppressor mutation
    À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
  • forward mutation
    ÀüÇâµ¹¿¬º¯ÀÌ
  • frequency mutation
    µ¹¿¬º¯À̺óµµ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ, À¯Àüüµ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • SPCA= serum prothrombin conversion a
    Ç÷ûÇÁ·ÎÆ®·ÒºóÀüÈ­ÃËÁø¼Ò.
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin complex concentrates
    ÇÁ·ÎÆ®·Òºó º¹ÇÕ ³óÃà(¹°)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • genetic mutation
    À¯ÀüÀû µ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ß¼º µ¹¿¬º¯ÀÌ.
  • plaque morphology mutation
    ÇöóÅ© ÇüÅ µ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • factor ii(prothrombin)
    Á¦2ÀÎÀÚ(ÇÁ·ÎÆ®·Òºó)
  • partial prothrombin time
    ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin complex concentrates
    ÇÁ·ÎÆ®·Òºó º¹ÇÕ ³óÃà(¹°)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • serum prothrombin conversion accelera
    Ç÷ûÇÁ·ÎÆ®·ÒºóÀüȯÃËÁø¼Ò(úìôè¡­ï®üµõµòä
  • back mutation
    ¿ªº¯ÀÌ
  • chromosomal mutation
    ¿°»öü(µ¹¿¬)º¯ÀÌ.
  • cold-sensitive mutation
    ÇÑ·©°¨¼ö¼º µ¹¿¬º¯ÀÌ
  • complementation of virus mutation
    ¹ÙÀÌ·¯½ºº¯ÀÌ (Áõ½Ä)º¸¿Ï(¡­ñòãÖÜÍèÇ).
  • conditional lethal mutation
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
    [¿¾ ¿ë¾î] À¯ÀüÀÚµ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • precursor of serum prothrombin conversion accelerator
    Ç÷û(úìôè)ÇÁ·ÎÆ®·Òºó Àüȯ°¡¼ÓÁ¦ Àü±¸¹°Áú(ï®üµÊ¥áÜð¥îñÏÌÚªòõ)
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin derivatives theory
    ÇÁ·ÎÆ®·Òºó À¯µµÃ¼ ÀÌ·Ð(ë¯Óôô÷×âÖå)
  • prothrombin factor
    ÇÁ·ÎÆ®·Òºó ÀÎÀÚ(ì×í­)
  • serum prothrombin conversion accelerator
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÃËÁøÁ¦(ï®üµõµòäð¥)
  • serum prothrombin converting factor
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í­)
  • anucleolate mutation
    ¹«ÇÙÀÎ º¯ÀÌ(Ùíú·ìÝܨì¶)
  • back mutation
    º¹±Íº¯ÀÌ(ÜÖÏýܨì¶)
  • chain termination mutation
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) º¯ÀÌ(ܨì¶)
  • constitutive mutation
    ±¸¼ºº¯ÀÌ(ϰà÷ܨì¶)
  • copy-error mutation
    º¹»ç¿À·ù º¯ÀÌ(ÜÜÞÐè¦×½Ü¨ì¶)
  • down promoter mutation
    ÇÏÇâÃËÁøÀÚ º¯ÀÌ(ù»ú¾õµòäí­Ü¨ì¶) (ÔÒ) promoter down mutation
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • forward mutation
    ³ªÅ¸³² º¯ÀÌ(ܨì¶)
  • frameshift mutation
    ƲÀ̵¿(ì¹ÔÑ) º¯ÀÌ(ܨì¶)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mutation
    µ¹¿¬ º¯ÀÌ
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PPCA plasma prothrombin conversion accelerator; proserum prothrombin conversion accelerator
ARMS adverse reaction monitoring system; amplification refractory mutation system
MF magnetic field; meat free; medium frequency; megafarad; membrane filler; merthiolate-formaldehyde [s...
TFM testicular feminization male; testicular feminization mutation; total fluid movement; transmission e...
PT   1) Prothrombin Time
  2) Physical Therapy; ¹°¸®¿ä¹ý
  3) Pulmonary...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ARMS Amplification Refractory Mutation System
DCP Des-gamma-carboxy prothrombin
MFD Mutation frequency decline
PCC Prothrombin Complex Concentrates
PT Prothrombin Time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • partial prothrombin time
    ºÎºÐ ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • prothrombin consumption test
    ÇÁ·ÎÆ®·Òºó ¼Òºñ ½ÃÇè
    ³»Àμº Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÇ Çü¼º·® ÃøÁ¤À» ÁÖµÈ ¸ñÀûÀ¸·Î ÇÏ´Â ½ÃÇèÀ¸·Î, ÀÀÇ÷ ¿Ï·á ÈÄ¿¡ ³²¾Æ ÀÖ´Â Ç÷û ÇÁ·ÎÆ®·ÒºóÀ» ÃøÁ¤ÇÑ´Ù. ÀÌ ½ÃÇèÀº Àüü Ç÷¾×¿¡ ´ëÇÏ¿© ÇàÇϱ⠶§¹®¿¡, Ç÷¼ÒÆÇÀÇ ÀÀÇ÷ ±â´É ÃøÁ¤¿¡ °£Á¢ÀûÀ¸·Î »ç¿ëµÈ´Ù.
  • prothrombin test
    ÇÁ·ÎÆ®·Òºó ½ÃÇè
    ÀÀÇ÷ ½Ã°£¿¡ ±âÃÊÇÑ ÇÁ·ÎÆ®·Òºó °ËÃâ ½ÃÇè.
  • two-stage prothrombin test
    ÀÌ ´Ü°è ÇÁ·ÎÆ®·Òºó ½ÃÇè
  • amber mutation
    ¾Ïº£¸£ µ¹¿¬º¯ÀÌ
  • auxotrophic mutation
    ¿µ¾ç ¿ä±¸ µ¹¿¬º¯ÀÌ
  • biochemical mutation
    »ýÈ­ÇÐÀû µ¹¿¬º¯ÀÌ
  • clear plaque mutation
    Åõ¸í ÇöóÅ© µ¹¿¬º¯ÀÌ
  • cold-sensitive mutation
    ÇÑ·© ¹Î°¨¼º µ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°ÇºÎ µ¹¿¬º¯ÀÌ
  • constitutive mutation
    ±¸¼ºÀû µ¹¿¬º¯ÀÌ
  • frameshift mutation
    °ñ°Ý ±¸Á¶ À̵¿ µ¹¿¬º¯ÀÌ
  • homoetic mutation
    È£¸Þ¿À½Ã½º µ¹¿¬º¯ÀÌ
  • missense mutation
    ¹Ì½º¼¾½º µ¹¿¬º¯ÀÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
proserum prothrombin conversion accelerator A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
prothrombin Clotting Factor II.
Origin: Gr. Thrombos = cloth in
(18 Nov 1997)
prothrombin accelerator <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
prothrombin and proconvertin test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
prothrombin deficiency A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs.
Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases.
(27 Sep 1997)
prothrombin test A quantitative test for prothrombin in the blood based on the clotting time of oxalated blood plasma in the presence of thromboplastin and calcium chloride; measures the integrity of the extrinsic and common pathways of coagulation.
See: prothrombin time.
Synonym: Quick's method, Quick's test.
(05 Mar 2000)
prothrombin time Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins.
(12 Dec 1998)
serum prothrombin conversion accelerator <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa.
Chemical name: Blood-coagulation factor VII
(12 Dec 1998)
acquired mutation A change in a gene or chromosome that occurs in a single cell after the conception of the individual. That change is then passed along to all cells descended from that cell. Acquired mutations are involved in the development of cancer.
(12 Dec 1998)
addition-deletion mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
addition mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
amber mutation <molecular biology> A mutation from a codon which codes for an amino acid into the amber codon UAG, which normally signals that the translation of mRNA into an amino acid chain should stop.
The mutation causes the amino acid chain to stop forming before it is actually completed.
(09 Oct 1997)
back mutation <molecular biology> A mutation that causes a mutant gene to revert to its original wild-type base sequence.
Compare: forward mutation.
(09 Oct 1997)
reading-frameshift mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
germinal mutation A mutation in the germ cells (the cells which will undergo meiosis to form the gametes). Such mutations are therefore passed on to offspring.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó(ÀÀÇ÷ ÀÎÀÚÀÇ ÀÏÁ¾)
  • mutation
    º¯°æ
  • forward mutation
    ÀüÁø µ¹¿¬ º¯ÀÌ
  • frameshift mutation
    ÇÁ·¹ÀÓ½ÃÇÁÆ® µ¹¿¬ º¯ÀÌ
  • missense mutation
    ¹Ì½º¼¾½º µ¹¿¬ º¯ÀÌ
  • mutation
    º¯È­;µ¹¿¬ º¯ÀÌ;º¯Á¾;¸ðÀ½ º¯È­
  • neutral mutation
    Á߸³µ¹¿¬º¯ÀÌ
  • vowel mutation
    =UMLAUT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á